Version 1
: Received: 20 April 2018 / Approved: 24 April 2018 / Online: 24 April 2018 (08:36:58 CEST)
How to cite:
Pakravan, M.; Naderi Beni, A.; Yazdani, S.; Esfandiari, H. Efficacy and Safety of Timolol-Dorzolamide Fixed-Combination Three Times a Day Versus Two Times a Day in Newly Diagnosed Open Angle Glaucoma. Preprints2018, 2018040310. https://doi.org/10.20944/preprints201804.0310.v1
Pakravan, M.; Naderi Beni, A.; Yazdani, S.; Esfandiari, H. Efficacy and Safety of Timolol-Dorzolamide Fixed-Combination Three Times a Day Versus Two Times a Day in Newly Diagnosed Open Angle Glaucoma. Preprints 2018, 2018040310. https://doi.org/10.20944/preprints201804.0310.v1
Pakravan, M.; Naderi Beni, A.; Yazdani, S.; Esfandiari, H. Efficacy and Safety of Timolol-Dorzolamide Fixed-Combination Three Times a Day Versus Two Times a Day in Newly Diagnosed Open Angle Glaucoma. Preprints2018, 2018040310. https://doi.org/10.20944/preprints201804.0310.v1
APA Style
Pakravan, M., Naderi Beni, A., Yazdani, S., & Esfandiari, H. (2018). Efficacy and Safety of Timolol-Dorzolamide Fixed-Combination Three Times a Day Versus Two Times a Day in Newly Diagnosed Open Angle Glaucoma. Preprints. https://doi.org/10.20944/preprints201804.0310.v1
Chicago/Turabian Style
Pakravan, M., Shahin Yazdani and Hamed Esfandiari. 2018 "Efficacy and Safety of Timolol-Dorzolamide Fixed-Combination Three Times a Day Versus Two Times a Day in Newly Diagnosed Open Angle Glaucoma" Preprints. https://doi.org/10.20944/preprints201804.0310.v1
Abstract
Purpose: To compare the therapeutic efficacy and safety of dorzolamide/timolol fixed-combination in newly diagnosed primary open angle glaucoma patients. Methods: In this prospective, interventional case series, newly diagnosed primary open angle glaucoma (POAG) patients that had not been treated for glaucoma were included. Patients were started on Cosopt twice a day (BID) for 1 month and then switched to three times a day (TDS) for additional 1 month. Patients underwent comprehensive ophthalmic examination, diurnal intraocular pressure (IOP), blood pressure (BP) and 24-hours heart rate (HR) measurements at baseline, month 1( BID), and month 2( TDS). IOP, systolic and diastolic pressures were measured at 8:00 AM,12:00 AM, 4:00 PM, 8:00 PM and 12:00 PM. Throughout the study, all adverse events were recorded and monitored by the investigators. Results: In 31 POAG patients that completed the study ,mean baseline IOP was 23.1±3.15 mmHg . IOP was decreased significantly 16.5 ± 2.21 at 1 month (P < 0.0001) and 13.9 ± 2.23 mmHg at 1 and 2 month follow up. (P < 0.0001) IOP was significantly lower in month 2 compared to month 1 (P = 0.0004). While Cosopt BID significantly reduced the mean 24-hour systolic BP and mean 24-hour HR from baseline (P < 0.0001), the mean 24-hour systolic BP and HR remained unchanged 2ith Cosopt TDS compared to BID (P = 0.62). Conclusions: Cosopt TDS has a superior IOP-lowering effect than Cosopt BID in POAG patients with comparable safety profile.
Keywords
primary open angle glaucoma; dorzolamide/timolol fixed combination; drug efficacy; safety
Subject
Medicine and Pharmacology, Ophthalmology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
